Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema  ( HAE )  - Intellia Therapeutics  ( NASDAQ:NTLA )